title: Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice.
abstract: BACKGROUND
  Abnormal p53 tumor suppressor gene expression as detected by immunohistochemistry is a possible prognostic factor in breast cancer. The difference in techniques used to evaluate the expression of mutated p53 protein is under intense scrutiny, as well as its uses either independently or in conjunction with other prognostic factors in breast cancer.
  
  
  OBJECTIVE
  To determine whether p53 immunohistochemistry can be used as a reliable indicator of the presence of mutated nuclear p53 protein, and whether this method can be performed reliably in a community hospital's clinical practice.
  
  
  METHODS
  ne hundred twenty-two cases of breast carcinoma were stained and analyzed for the presence of p53 protein using DO-7 (Dako Corporation, Carpinteria, Calif) p53 antibody.
  
  
  RESULTS
  Of the 122 cases of invasive carcinoma studied, 23 (18.7%) were positive for p53, and 16 (16.3%) of 98 cases with coexisting ductal carcinoma in situ were positive for p53. This finding is in agreement with comparable published studies.
  
  
  CONCLUSIONS
  Based on the results of this study, we conclude that p53 immunohistochemistry qualifies as a diagnostic technique suitable for clinical practice in a community hospital. Its detection may be particularly promising in clinical trials of new molecular therapies directed at the p53 tumor suppressor gene.
authors.affiliation: Wake Forest University School of Medicine, Forsyth Medical Center, Winston-Salem, NC 27103, USA. abartley@wfubmc.edu
authors.forename: Angela N
authors.initials: AN
authors.lastname: Bartley
authors.forename: Dennis W
authors.initials: DW
authors.lastname: Ross
mesh_terms: D000328:Adult; D001706:Biopsy; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002278:Carcinoma in Situ / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000235:genetics* / Q000378:metabolism / Q000556:secondary; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006764:Hospitals, Community; D006801:Humans; D007124:Immunoenzyme Techniques; D009154:Mutation; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D016159:Tumor Suppressor Protein p53